| Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody G Garrido, A Rabasa, B Sánchez, MV López, R Blanco, A López, ... The Journal of Immunology 187 (10), 4954-4966, 2011 | 99 | 2011 |
| SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies Y Valdes-Balbin, D Santana-Mederos, L Quintero, S Fernández, ... ACS Chemical Biology 16 (7), 1223-1233, 2021 | 83 | 2021 |
| Nimotuzumab: beyond the EGFR signaling cascade inhibition Z Mazorra, L Chao, A Lavastida, B Sanchez, M Ramos, N Iznaga, ... Seminars in oncology 45 (1-2), 18-26, 2018 | 62 | 2018 |
| Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant BS Ramírez, ES Pestana, GG Hidalgo, TH García, RP Rodríguez, ... International journal of cancer 119 (9), 2190-2199, 2006 | 62 | 2006 |
| T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies G Garrido, P Lorenzano, B Sánchez, I Beausoleil, DF Alonso, R Pérez, ... Cancer Immunology, Immunotherapy 56, 1701-1710, 2007 | 57 | 2007 |
| Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines Y Valdes-Balbin, D Santana-Mederos, F Paquet, S Fernandez, Y Climent, ... ACS central science 7 (5), 757-767, 2021 | 50 | 2021 |
| Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein … E Suarez Pestana, U Greiser, B Sanchez, LE Fernandez, A Lage, R Perez, ... British journal of cancer 75 (2), 213-220, 1997 | 50 | 1997 |
| A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial A Chang-Monteagudo, R Ochoa-Azze, Y Climent-Ruiz, ... The Lancet Regional Health–Americas 4, 2021 | 41 | 2021 |
| Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials M Eugenia-Toledo-Romaní, L Verdecia-Sánchez, M Rodríguez-González, ... Vaccine 40 (31), 4220-4230, 2022 | 37 | 2022 |
| Induction of immune recognition of self-epidermal growth factor II: characterization of the antibody response and the use of a fusion protein G González, OL Pardo, A Lage, B Sanchez, JL GARCIA, I BEAUSOLEIL Vaccine research 6 (2), 91-100, 1997 | 37 | 1997 |
| Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine BS Ramírez, YA Alpízar, DRH Fernández, GG Hidalgo, AR Capote, ... Vaccine 26 (38), 4918-4926, 2008 | 36 | 2008 |
| 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies G Garrido, B Sanchez, HM Rodriguez, P Lorenzano, D Alonso, ... Hybridoma and Hybridomics 23 (3), 168-175, 2004 | 35 | 2004 |
| Targeting HER3, a catalytically defective receptor tyrosine kinase, prevents resistance of lung cancer to a third-generation EGFR kinase inhibitor D Romaniello, I Marrocco, N Belugali Nataraj, I Ferrer, D Drago-Garcia, ... Cancers 12 (9), 2394, 2020 | 34 | 2020 |
| Upregulation of HLA class I expression on tumor cells by the anti-EGFR antibody nimotuzumab G Garrido, A Rabasa, C Garrido, L Chao, F Garrido, ÁM García-Lora, ... Frontiers in pharmacology 8, 595, 2017 | 34 | 2017 |
| Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms G Garrido, A Rabasa, C Garrido, A Lopez, L Chao, ÁM García-Lora, ... Oncogene 33 (24), 3129-3139, 2014 | 34 | 2014 |
| Induction of immune recognition of self epidermal growth factor (EGF): effect on EGF-biodistribution and tumor growth G González, B Sánchez, E Suárez, I Beausoleil, O Perez, M Lastre Vaccine research 5 (4), 233-244, 1996 | 33 | 1996 |
| Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivative thereof having anti-tumor activity and use thereof in the therapy of malignant … ABL Davila, GG Marinello, BS Ramirez, ES Peztana, IB Delgado, ... US Patent 5,894,018, 1999 | 31 | 1999 |
| Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b … R Ochoa-Azze, A Chang-Monteagudo, Y Climent-Ruiz, ... The Lancet Respiratory Medicine 10 (8), 785-795, 2022 | 23 | 2022 |
| A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity S Pérez-Rodríguez, M de la Caridad Rodríguez-González, R Ochoa-Azze, ... Vaccine 40 (13), 2068-2075, 2022 | 23 | 2022 |
| Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein … R Puga-Gómez, Y Ricardo-Delgado, C Rojas-Iriarte, ... International Journal of Infectious Diseases 126, 164-173, 2023 | 22 | 2023 |
